Close Menu

expansion

The Swiss-American bioinformatics company touts its networks of multimodal data and numerous partnerships as it looks to support "data-driven medicine."

The company recently received FDA Emergency Use Authorization for its SARS-CoV-2 PCR test while its data-driven COVID-19 research initiative is moving along.

The firm's technology uses ex vivo organ culture to model cancer growth and predict a patient's tumor response to chemotherapy and targeted drugs. 

Personalis said that it plans to form a wholly owned subsidiary in Shanghai, including a laboratory for local customers to use its ImmunoID NeXT platform.

The new Qlucore Diagnostics software builds on the recently updated Qlucore Omics Explorer platform, initially to help clinicians diagnose and treat leukemia.

Freshly minted as a "unicorn," the Utah healthcare data analytics powerhouse is building up a new life sciences division to aid biotech development and precision medicine.

The UK-based maker of clinical genomics interpretation software is moving into the US and China after carefully researching the differences from European markets.

The Shenzhen-based company offers personal genomics services in China that are similar to those provided by 23andMe, Ancestry, and Helix in the US.

The change will be felt most immediately in Europe, where the Dutch molecular diagnostics company recently secured a CE-IVD mark for its MammaPrint BluePrint kit.

Centogene opened a Boston office in December and plans to open a lab there in a few months as it awaits an FDA decision on its clinical tool.

Pages

Nature News reports the US National Institutes of Health is investing in studies of the long-term effects of COVID-19.

The National Health Service is to offer Novartis's Zolgensma for spinal muscular atrophy later this year, according to the Guardian.

Taiwan is to launch a pilot program offering genetic testing to cancer patients, the Taipei Times reports.

In PLOS this week: loci linked to protection against tuberculosis, identification of loci associated with increased risk of squamous cell carcinoma of the aerodigestive tract, and more.